Claims for Patent: 6,268,212

Summary for Patent: 6,268,212

Title:	Tissue specific transgene expression
Abstract:	This invention provides a mammal with enhanced liver expression of a transgene. Also provided are 1) a nucleic acid sequence useful in enhancing liver specific expression of a transgene, and 2) a vector containing this nucleic acid sequence.
Inventor(s):	Simonet; William Scott (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	08/221,767
Patent Claims:	1. A nucleic acid sequence comprising the hepatocyte-specific control region (HCR) enhancer sequence disclosed in SEQ ID NO 1 or a biologically active fragment thereof, operably linked to a promoter and a transgene, wherein the transgene comprises a nucleotide sequence encoding a polypeptide involved in immune response, hematopoiesis, inflammation, cell growth and proliferation, cell lineage differentiation, or stress response, and wherein the promoter is selected from the group of promoters consisting of the promoters of: ApoA-I, ApoA-II, ApoA-III, ApoA-IV, ApoB-100, ApoC-I, ApoC-II, ApoC-III, ApoE, albumin, alpha feto protein, PEPCK, transthyretin, SV40, CMV and TK. 2. The nucleic acid sequence of claim 1 wherein the polypeptide is selected from the group consisting of: interleukin 1, interleukin 2, interleukin 3, interleukin 4, interleukin 5, interleukin 6, interleukin 7, interleukin 8, interleukin 9, interleukin 10, interleukin 11, interleukin 12, ENA-78, interferon-.alpha., interferon-.beta., interferon-.gamma., granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulatory factor, macrophage colony stimulating factor, stem cell factor, keratinocyte growth factor (KGF), afamin (AFM), monocyte chemoattractant protein (MCP-1), tumor necrosis factor (TNF), and biologically active fragments thereof. 3. A nucleic acid sequence comprising the HCR enhancer sequence disclosed in SEQ ID NO 1 or a biologically active fragment thereof, the human ApoE promoter, the human ApoE intron 1 operatively linked at its 5' end to the human ApoE exon 1 and at its 3' end to a segment of the human ApoE exon 2 wherein the ApoE exon 2 segment comprises the 5' sequences of the ApoE exon 2, and a nucleotide sequence encoding human IL-8. 4. A nucleic acid sequence comprising the HCR enhancer sequence disclosed in SEQ ID NO 1 or a biologically active fragment thereof, the human ApoE promoter, the human ApoE intron 1 operatively linked at its 5' end to the human ApoE exon 1 and at its 3' end to a segment of the human ApoE exon 2 wherein the ApoE exon 2 segment comprises the 5' sequences of the ApoE exon 2, and the nucleotide sequence encoding human KGF. 5. A nucleic acid sequence comprising the HCR enhancer sequence disclosed in SEQ ID NO 1 or a biologically active fragment thereof, the human ApoE promoter, the human ApoE intron 1 operatively linked at its 5' end to the human ApoE exon 1 and at its 3' end to a segment of the human ApoE exon 2 wherein the ApoE exon 2 segment comprises the 5' sequences of the ApoE exon 2, and the nucleotide sequence encoding human MCP-1. 6. A vector comprising the nucleic acid sequence of claim 1. 7. A vector comprising the nucleic acid sequence of claim 2. 8. A vector comprising the nucleic acid sequence of claim 3. 9. A vector comprising the nucleic acid sequence of claim 4. 10. A vector comprising the nucleic acid sequence of claim 5. 11. A recombinant prokaryotic host cell comprising the nucleic acid of claims 1, 2, 3, 4, or 5. 12. A recombinant eukaryotic host cell comprising the nucleic acid of claims 1, 2, 3, 4, or 5. 13. A recombinant prokaryotic host cell comprising the vector of claims 6, 7, 8, 9, or 10. 14. A recombinant eukaryotic host cell comprising the vector of claims 6, 7, 8, 9, or 10.

Details for Patent 6,268,212

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-07-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-07-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-07-31